PROTACs for Innovative Drug Development: Current Trends and Future Prospects

Targeted protein degradation, particularly through proteolysis-targeting chimeras (PROTACs) has emerged as a revolutionary approach in drug discovery and development over the past two decades. This technology harnesses the cell’s natural protein degradation machinery to selectively eliminate disease-causing proteins, offering several advantages over traditional small molecule inhibitors. As the field rapidly advances, several key trends and future directions are shaping the landscape of targeted protein degradation research and therapeutics. The scientific essay evaluates the current and future trends based on recent research articles on PROTAC.

A. Current Trends in Targeted Protein Degradation (TPD)/PROTAC

Targeted protein degradation (TPD) encompasses a variety of strategies designed to eliminate specific proteins from cells. These TPD methods include PROTACs (PROteolysis TArgeting Chimeras), Molecular Glues, LYTACs (Lysosome-Targeting Chimeras), AbTACs (Antibody-based PROTACs), AUTACs (Autophagy-TArgeting Chimeras), and more. A list of TPD methods is listed here.

1. PROTAC Design and Optimization

Recent advancements in PROTAC design have focused on improving potency, selectivity, and pharmacokinetic properties. Researchers have developed novel strategies to enhance PROTAC efficacy:

• Linker Optimization: A study by East China Normal University introduced a highly efficient photocatalytic one-pot method for constructing PROTACs with triazole-based linkers, significantly simplifying synthesis and reducing production time (74).
• E3 Ligase Expansion: Northwestern University researchers identified FBXO22 as a novel E3 ligase for PROTAC development, expanding the toolbox for targeted protein degradation (58).
• Oral Bioavailability: AstraZeneca scientists established the “Rule-of-oral-PROTACs,” providing guidelines for designing orally bioavailable PROTACs, a crucial step towards clinical application (18).
• Covalent PROTACs: China Pharmaceutical University developed covalent MLKL-targeting PROTACs, demonstrating their potential in treating necroptosis-related diseases (21).

   
  Targeted Protein Degradation (TPD) Drug Discovery & Development Assay Services Offered by Marin Biologic Laboratories | Click for Details

2. Targeting Challenging Proteins

PROTACs are being developed to target previously undruggable or challenging proteins:

• KRAS Targeting: Sun Yat-sen University Cancer Center introduced a tumor-targeting KRAS degrader effective against a wide range of KRAS mutants (60).
• Transcription Factor Degradation: Yale University researchers developed PROTACs targeting MAGE-A3, a type I melanoma antigen (MAGE) and a transcription factor associated with cancer (9).
• Viral Protein Degradation: Stanford University School of Medicine created PROTACs targeting viral envelope proteins, demonstrating broad-spectrum antiviral activity (63).

3. Cancer Therapy Targets

Recent research has focused on developing PROTACs targeting various proteins implicated in cancer progression:

• Bromodomain-containing protein 4 (BRD4): A BRD4-specific PROTAC, 6b, demonstrated efficacy in suppressing basal-like breast cancer growth by downregulating the KLF5 transcription factor (32, 49,53.55, 58, 59, 75).
• Enhancer of zeste homolog 2 (EZH2): PROTACs MS177 and MS8815 showed promise in overcoming tamoxifen resistance in breast cancer by degrading both EZH2 and FOXM1 (52).
• MAGE-A3: Yale University researchers developed PROTACs targeting MAGE-A3, a cancer-associated protein, potentially enhancing immunotherapy by increasing antigen presentation (9).
• Yes-associated protein (YAP): University of Florida and Tulane University researchers created YAP degraders, demonstrating potent antiproliferative effects in YAP-driven cancer cell lines and xenograft models (7, 8).
• Mixed-lineage protein kinase 3 (MLK3): Polish Academy of Sciences developed CEP1347-VHL-02, a selective MLK3 degrader showing promise in triple-negative breast cancer therapy (6).
• Nuclear receptor binding SET domain protein 2 (NSD2, also known as MMSET, WHSC1): University of Pennsylvania researchers identified NSD1/2 as viable co-targets in advanced prostate cancer, with a dual PROTAC degrader showing preferential cytotoxicity in AR-dependent models (44).
• Werner syndrome helicase (WRN): The University of Dundee demonstrated the potential of WRN-specific PROTAC compounds for treating microsatellite instability cancers (45).

4. Non-Cancer Therapy Targets

1. Neurodegenerative Diseases:

• α-synuclein: The degradation by small tag ABEL (DESTABEL) platform demonstrated efficient degradation of α-synuclein in primary neurons and the adult mouse brain, relevant to Parkinson’s disease (104).
• Amyloid fibrils: FibrilPaint20 (FP20) targets amyloid fibrils for ubiquitination and degradation, potentially applicable to various neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Corticobasal Degeneration (95).

2. Inflammatory and Autoimmune Diseases:

• Soluble epoxide hydrolase (sEH): Potent sEH-PROTACs were developed for simultaneous degradation of dual catalytic domains, offering therapeutic potential for inflammation-related diseases (103).
• Bruton tyrosine kinase (BTK): A novel BTK PROTAC degrader showed potential for treating autoimmune diseases in lupus and diffuse alveolar hemorrhage models (28, 61, 84).

3. Liver Diseases:

A novel nuclear receptor coactivator 4 (NCOA4) degrader (V3) was developed as a potent ferroptosis inhibitor for treating acute liver injury (21, 22).

4. Viral Infections:

Viral envelope proteins: PROTACs targeting the dengue virus envelope (E) protein showed broad-spectrum activity against multiple flaviviruses (63, 98).

5. Cardiovascular Diseases:

A novel stimulator of interferon genes (STING) degrader (AK59) was developed, potentially applicable to diseases involving STING dysregulation, which can include certain cardiovascular conditions (66).

6. Metabolic Disorders:

Next-generation soluble epoxide hydrolase (sEH) PROTACs were developed with potential applications in metabolic disorders (103).

7. Androgenic Alopecia:

A peptide-based PROTAC targeting the androgen receptor (AR) was developed for androgenic alopecia treatment (46).

8. Bacterial Infections:

PROTACs were explored for antibiotic development by targeting essential proteins in Mycobacterium smegmatis, with potential applications for Mycobacterium tuberculosis (68).

5. Novel Delivery Methods

Innovative delivery systems are being developed to enhance PROTAC efficacy and specificity:

• Extracellular Vesicle Delivery: University of Florida scientists developed a microfluidic droplet-based electroporation system for loading PROTACs into extracellular vesicles, improving in vivo targeting and stability (8).
• Nanoparticle Delivery: East China Normal University researchers created polymer-conjugated PROTAC prodrug nanoparticles for tumor-targeted delivery, enhancing bioavailability and specificity (53).
• Liposomal Delivery: Peking University developed a liposome-based platform (LipoSM-PROTAC) for PROTAC delivery, demonstrating improved tumor inhibition and reduced toxicity in vivo (27).
• Region-Confined PROTAC Nanoplatform: East China Normal University presented a nanoplatform integrating ROS-activatable and hypoxia-responsive PROTAC prodrugs to enhance tumor specificity and overcome tumor heterogeneity (53).
• Amphiphilic PROTAC: Sichuan University developed B1-PEG, an amphiphilic PROTAC that self-organizes into micelles and releases its active form in tumor-specific environments, demonstrating superior bioavailability (41).

6. Novel or Innovative Forms of PROTAC

Researchers have introduced innovative platforms to expand the scope of targeted protein degradation:

• Lysosome and Proteasome Pathways: The combination of lysosome-targeting strategies (e.g., Lysosomal Protein Degradation and Glut1-Facilitated Lysosomal Degradation) with the more common proteasome-targeting approaches indicates growing interest in utilizing multiple degradation pathways for therapeutic intervention. Examples are Lysosome Membrane Targeting Chimeras (LYMTACs) peptide-mediated small molecule lysosome-targeting chimeras (PSMLTACs) (4, 11, 37, 60, 105).
• DESTABEL: Genentech introduced a platform using small tags and bacterial E3 ligase for efficient protein degradation, demonstrating efficacy in degrading α-synuclein in neurons (104).
• PNCA: M6P Therapeutics and University of Washington researchers developed Phosphorylated N-glycosylated Peptide Chimeric Antibodies (PNCA) for producing bifunctional antibodies that facilitate lysosomal degradation of extracellular and membrane proteins (93).
• Viral E3 Pan-Essential Removing Targeting Chimeras (VIPER-TACs): Amgen introduced bi-functional molecules leveraging viral E3 ligases for selective protein degradation in diseased cells, potentially expanding the therapeutic window for TPD (98).
• RIPTACs: Yale University introduced Regulated Induced Proximity Targeting Chimeras (RIPTACs), which induce a stable ternary complex between a target protein and an essential survival protein, leading to selective cell death in tumor cells (73).
• Artificial lncRNAs: Shenzhen University researchers developed artificial long non-coding RNAs (alncRNAs) for targeted degradation of oncogenic proteins, offering an alternative to protein-based chimeras (14).
• P-NADs: King Abdullah University of Science and Technology introduced PUX-based Nanobody Degraders (P-NADs) for ubiquitin-independent targeted protein degradation via the CDC48 machinery (77).
• Covalent PROTACs and Molecular Glues: Several studies, such as the use of covalent PROTACs and molecular glues (e.g., 14–3–3 Molecular Glue), emphasize the importance of irreversible or long-lasting protein-protein interactions for enhanced degradation. These molecules offer new avenues for targeting proteins with high therapeutic potential (53).
• Membrane and Intracellular Protein Targeting: The development of PROTACs targeting membrane proteins (e.g., PD-L1, VEGFR2) and intracellular proteins (e.g., CD71, PTK7) signifies an expansion in the scope of degradation targets. Membrane protein degradation is especially important in cancer immunotherapy.
• Improved Pharmacokinetics: Studies on oral bioavailability, such as the Rule-of-Oral-PROTACs, reflect the ongoing effort to improve the pharmacokinetic properties of PROTACs. Achieving good bioavailability is critical for clinical translation, and researchers are optimizing molecular properties to ensure better delivery and effectiveness (18).
• Multifunctional Approaches: Novel molecular platforms, such as LYTACs, integrin α3β1-facilitated bispecific aptamer chimeras (ITGBACs) and bioPROTACs, are being developed to offer multifunctional approaches to protein degradation, combining elements such as aptamer chimeras or bio-circuits to fine-tune degradation processes and therapeutic responses (4, 26, 57).
• PROTACs in Immunotherapy: The trend of using PROTACs to enhance immunotherapy is growing, with studies exploring the degradation of immunosuppressive proteins like PD-L1. These approaches aim to augment immune responses and improve cancer treatment outcomes (38).

7. AI-Based PROTACs

Artificial intelligence and computational methods are playing an increasingly important role in PROTAC design and optimization:

• AI-Driven Design: AnHorn Medicines demonstrated an integrated approach combining superimposition techniques and deep neural networks to design structurally diverse PROTAC molecules (1).
• Computational Tools: A University of Toronto study benchmarked computational tools for PROTAC ternary complex modeling, highlighting both promises and challenges in predicting PROTAC structures (15, 72).
• Machine Learning for ADME Prediction: Novartis evaluated machine learning models for predicting ADME properties of targeted protein degraders, showing potential in supporting TPD design (56).
• In-Silico Molecular Glue Design: Sravathi AI Technology introduced MOLDE, an in-silico method for designing molecular glues, potentially accelerating the discovery of novel degraders (99).
• AI-Driven Peptide-Based PROTAC: Xi’an Jiaotong University integrated AI tools like ProteinMPNN and RFdiffusion to identify binding peptides for PROTAC development, demonstrating potential in advancing personalized medicine (42).

B. Emerging Trends and Future Directions

Based on current research, several trends are likely to shape the future of PROTAC and TPD development:

1. Expanding E3 Ligase Recruitment: Future research will focus on identifying novel E3 ligases, particularly tissue-specific ones, to expand the range of PROTAC targets. This could enable tissue-selective degradation, reducing off-target effects and improving therapeutic precision.
2. Tissue-Specific Degradation: Development of strategies for tissue-specific protein degradation, such as the VIPER-TACs approach, may improve therapeutic windows and reduce systemic toxicity.
3. Combination Therapies: Integrating PROTACs with other therapeutic modalities, such as immunotherapy or small molecule inhibitors, could lead to more effective treatment strategies.
4. Improved Oral Bioavailability: AstraZeneca’s “Rule-of-oral-PROTACs” provides guidelines for designing orally bioavailable PROTACs, a crucial step towards clinical application.
5. Targeting Challenging Proteins: PROTACs targeting previously undruggable proteins, like transcription factors and membrane proteins, may open new therapeutic avenues.
6. Expanding Applications: PROTAC research is expanding beyond cancer therapy into areas like antiviral development, neurodegenerative diseases, and autoimmune disorders.
7. Improved Understanding of Degradation Mechanisms: Studies on protein half-life and catalytic rates in targeted degradation will inform future PROTAC design strategies.
8. AI-Enhanced Personalized Medicine: AI-driven drug discovery platforms using patient genomic and proteomic data could develop personalized PROTACs, advancing individualized treatments.
9. Targeting Protein-Protein Interactions: Future PROTAC development may focus on protein-protein interactions, particularly in transcription factors and regulatory complexes.
10. Developing Non-Canonical Degradation Pathways: Exploration of non-canonical degradation systems, such as autophagy and lysosomal pathways, could broaden PROTAC applicability.
11. In Vivo Targeting and Delivery Systems: Innovations like liposome-based platforms and nanoparticle carriers (e.g., LipoSM-PROTACs) will improve in vivo stability and delivery, with advanced techniques like ultrasound-activatable prodrugs enhancing precision.
12. PROTACs as Modulators of Immune Function: PROTACs designed to modulate immune checkpoints or immune signaling proteins will advance their role in combination therapies, particularly in cancer immunotherapy and autoimmune diseases.
13. Bifunctional Degraders and Transcytosis Across the Blood-Brain Barrier (BBB): Multifunctional PROTACs capable of crossing the BBB could revolutionize treatments for central nervous system (CNS) diseases, including Alzheimer’s and Parkinson’s.
14. Regulating Cellular Signaling in Real-Time: Advances in bioengineering may lead to programmable degraders that can dynamically modulate cellular signaling pathways in response to environmental cues.
15. Optimizing Chameleonicity and Degrader Efficiency: Future PROTAC design will focus on optimizing chameleonic properties to improve bioavailability and efficiency, with predictive tools enhancing degrader efficacy.